Dr Philippe Moreau, Centre Hospitalier Universitaire de Nantes, France, gives Prof Gareth Morgan, Royal Marsden Hospital, London, UK, his thoughts on the myeloma session held on the 3^rd day of ASCO 2012.

He first outlines the promising results from the carfilzomib combination studies, eg, with MP and with len dex, and comments on results with the investigational oral proteasome inhibitor, MLN9708, as well as recent data with pomalidomide and panobinostat.

Dr Moreau goes on to outline initial results presented at ASCO of the bendamustine, bortezomib, dexamethasone (BVD) study in elderly patients with relapsed/refractory multiple myeloma which showed a 67% response rate in this patient group after four cycles.

This programme was made possible with an educational grant provided by Mundipharma.